Sutro Biopharma, Inc. (STRO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. William J. Newell J.D. | CEO & Director | 1.07M | -- | 1958 |
| Ms. Jane Chung R.Ph. | President & COO | 934.64k | -- | 1972 |
| Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder | -- | -- | -- |
| Mr. Edward C. Albini M.B.A | CFO & Secretary | 596.4k | -- | 1958 |
| Dr. Venkatesh Srinivasan Ph.d. | Chief Technical Operations Officer | -- | -- | -- |
| Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer | -- | -- | -- |
| Mr. David Pauling J.D., M.A. | General Counsel | -- | -- | -- |
| Ms. Linda A. Fitzpatrick | Chief People & Communications Officer | 595.79k | -- | 1957 |
| Dr. Nicki Vasquez Ph.D. | Chief Portfolio Strategy & Alliance Officer | -- | -- | 1963 |
| Dr. Anne Elizabeth Borgman-Hagey M.D. | Chief Medical Officer | -- | -- | 1969 |
Sutro Biopharma, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 302
Description
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 26, 2024DEF 14A: Proxy StatementsSee Full Filing
- Apr 02, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 25, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 09, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 24, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing